Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company.

A number of research firms have recently issued reports on BAYRY. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. Finally, Jefferies Financial Group upgraded shares of Bayer Aktiengesellschaft to a “hold” rating in a research report on Friday, May 29th.

Bayer Aktiengesellschaft Stock Performance

Bayer Aktiengesellschaft stock opened at $10.56 on Friday. The firm’s 50-day moving average is $10.97 and its 200-day moving average is $11.42. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.63 and a current ratio of 1.05. Bayer Aktiengesellschaft has a 1 year low of $7.19 and a 1 year high of $14.85. The company has a market cap of $41.51 billion, a P/E ratio of -16.50, a PEG ratio of 3.39 and a beta of 0.59.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. The company had revenue of $15.73 billion for the quarter, compared to the consensus estimate of $15.77 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, equities analysts expect that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.